Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression

Niu ChunYan; Liu Qin; Luo XiaoChun

doi:10.3969/j.issn.1001-5256.2020.10.043

Volume 36 Issue 10

Oct. 2020

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(10): 2356-2359

PDF( 228 KB)

Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression

DOI: 10.3969/j.issn.1001-5256.2020.10.043

Department of Gastroenterology,Nanjing Lishui People's Hospital & Lishui Branch of Zhongda Hospital Affiliated to Southeast University
Department of Gastroenterology,The First Affiliated Hospital of Xi'an Medical University
Xiamen University Medical College
Center of Digestive Endoscopy,Xiang'an Hospital Affiliated to Xiamen University

Research funding:

Received Date: 2020-04-07
Published Date: 2020-10-20

Abstract

Abstract

Recent studies have shown that metabolic syndrome( MetS),e. g.,obesity,diabetes mellitus,insulin resistance,and nonalcoholic fatty liver disease( NAFLD),and drinking coexist in a considerable number of individuals,suggesting the overlap of alcoholic liver disease( ALD) and NAFLD promotes the development and progression of fatty liver disease and aggravates the adverse outcome of fatty liver disease in a synergistic and interactive way. The evolution of the disease spectrum of fatty liver disease challenges the exclusive diagnosis system which divides fatty liver disease into ALD and NAFLD. This article summarizes the research advances in recent years and introduce the latest international consensus on the renaming of NAFLD,aiming to pay attention to the influence of drinking and MetS on NAFLD,put forward our insights into the diagnosis of fatty liver disease,and thus provide a new basis for reexamination the diagnosis and individualized treatment of fatty liver disease.
- fatty liver,
- metabolic syndrome X,
- alcohol drinking,
- obesity

FullText(HTML)

References(38)

References

[1] ASRANI SK,DEVARBHAVI H,EATON J,et al. Burden of liver diseases in the world[J]. J Hepatol,2019,70(1):151-171.

[2] OECD. Obesity Update[EB/OL]. https://www. oecd. org/els/health-systems/Obesity-Update-2017. pdf. Accessed August 1,2019.

[3] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.

[4] World Health Organization. Global status report on alcohol and health 2018[EB/OL]. https://www. who. int/substance_abuse/publications/global_alcohol_report/gsr_2018. en/．Accessed August 1,2019.

[5] SHIELD KD,RYLETT M,REHM J. Public health successes and missed opportunities. Trends in alcohol consumption and attributable mortality in the WHO European Region,1990-2014(2016)[EB/OL]. http://www. euro. who. int/en/home.

[6] SINGAL AK,BATALLER R,AHN J,et al. ACG clinical guideline:Alcoholic liver disease[J]. Am J Gastroenterol,2018,113(2):175-194.

[7] CAO HX,FAN JG. Alcoholic fatty liver disease with nonalcoholic fatty liver disease and obesity[J]. J Clin Hepatol,2019,35(3):478-480.(in Chinese)曹海霞，范建高．酒精性肝病合并非酒精性脂肪性肝病和肥胖[J]．临床肝胆病杂志，2019,35(3):478-480.

[8] SINGH A,AMIN H,GARG R,et al. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease[J]. Dig Dis Sci,2020.[Online Ahead of Print]

[9] YAMADA K,MIZUKOSHI E,SEIKE T,et al. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease[J]. PLo S One,2018,13(1):e0191026.

[10] BELLENTANI S,SACCOCCIO G,MASUTTI F,et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy[J]. Ann Intern Med,2000,132(2):112-117.

[11] FAZZINO TL,FLEMING K,SHER KJ,et al. Heavy drinking in young adulthood increases risk of transitioning to obesity[J].Am J Prev Med,2017,53(2):169-175.

[12] LOOMBA R,BETTENCOURT R,BARRETT-CONNOR E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults:The Rancho Bernardo Study[J]. Aliment Pharmacol Ther,2009,30(11-12):1137-1149.

[13]BERG F,HELENIUS-HIETALA J,PUUKKA P,et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population[J]. Hepatology,2018,67(6):2141-2149.

[14]BERG F,FRKKILM,MNNISTV. Interaction between alcohol use and metabolic risk factors for liver disease:A critical review of epidemiological studies[J]. Alcohol Clin Exp Res,2020,44(2):384-403.

[15] YOUNOSSI ZM,STEPANOVA M,ONG J,et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease[J]. Clin Gastroenterol Hepatol,2019,17(8):1625-1633. e1.

[16] DULY AM,ALANI B,HUANG EY,et al. Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity[J]. Nutr Diabetes,2015,5:e154.

[17]BERG F,PUUKKA P,SAHLMAN P,et al. Metabolic risk factors for severe liver disease among alcohol risk users in the general population[J]. J Hepatol,2019,70(Suppl):e273.

[18]BERG F,PUUKKA P,SALOMAA V,et al. Risks of light and moderate alcohol use in fatty liver disease:Follow-up of population cohorts[J]. Hepatology,2020,71(3):835-848.

[19] SAHLMAN P,NISSINEN M,PUUKKA P,et al. Genetic and lifestyle risk factors for advanced liver disease among men and women[J]. J Gastroenterol Hepatol,2020,35(2):291-298.

[20] BAECKER A,LIU X,LA VECCHIA C,et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors[J]. Eur J Cancer Prev,2018,27(3):205-212.

[21] FORD ES,GILES WH,DIETZ WH. Prevalence of the metabolic syndrome among US adults:Findings from the third National Health and Nutrition Examination Survey[J]. JAMA,2002,287(3):356-359.

[22] BOYLE M,MASSON S,ANSTEE QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome:Cofactors for progressive fatty liver disease[J]. J Hepatol,2018,68(2):251-267.

[23] LONGATO L,RIPP K,SETSHEDI M,et al. Insulin resistance,ceramide accumulation,and endoplasmic reticulum stress in human chronic alcohol-related liver disease[J]. Oxid Med Cell Longev,2012,2012:479348.

[24] NAVEAU S,GIRAUD V,BOROTTO E,et al. Excess weight risk factor for alcoholic liver disease[J]. Hepatology,1997,25(1):108-111.

[25] TESCHKE R. Alcoholic liver disease:Alcohol metabolism,cascade of molecular mechanisms,cellular targets,and clinical aspects[J]. Biomedicines,2018,6(4):106.

[26] MIYAKE T,KUMAGI T,HIROOKA M,et al. Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease[J]. J Gastroenterol,2016,51(11):1090-1100.

[27]BERG F,FRKKILM. Drinking and obesity:Alcoholic liver disease/nonalcoholic fatty liver disease interactions[J]. Semin Liver Dis,2020,40(2):154-162.

[28] MAHLI A,HELLERBRAND C. Alcohol and obesity:A dangerous association for fatty liver disease[J]. Dig Dis,2016,34Suppl 1:32-39.

[29] ALBILLOS A,GOTTARDI A,RESCIGNO M. The gut-liver axis in liver disease:Pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.

[30] PARKER R,KIM SJ,GAO B. Alcohol,adipose tissue and liver disease:Mechanistic links and clinical considerations[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):50-59.

[31] LOSURDO G,CASTELLANETA A,RENDINA M,et al. Systematic review with meta-analysis:De novo non-alcoholic fatty liver disease in liver-transplanted patients[J]. Aliment Pharmacol Ther,2018,47(6):704-714.

[32] KRAWCZYK M,LIEBE R,LAMMERT F,et al. Towards genetic prediction of non-alcoholic fatty liver disease trajectories:PNPLA3 and beyond[J]. Gastroenterology,2020,158(7):1865-1880.

[33] RAUSCH V,MUELLER S. Suppressed fat mobilization due to PNPLA3 rs738409-associated liver damage in heavy drinkers:The liver damage feedback hypothesis[J]. Adv Exp Med Biol,2018,1032:153-172.

[34] BIBBS,IANIRO G,DORE MP,et al. Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease[J].Mediators Inflamm,2018,2018:9321643.

[35] LITWINOWICZ K,CHOROSZY M,WASZCZUK E. Changes in the composition of the human intestinal microbiome in alcohol use disorder:A systematic review[J]. Am J Drug Alcohol Abuse,2020,46(1):4-12.

[36]BERG F,PUUKKA P,SALOMAA V,et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease[J]. Clin Gastroenterol Hepatol,2020,18(4):995-997. e2.

[37] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.

[38] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (500) PDF downloads(79)

Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression

DOI: 10.3969/j.issn.1001-5256.2020.10.043

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression

DOI: 10.3969/j.issn.1001-5256.2020.10.043

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content